




PHARMACEUTICAL 2019

Oncternal Therapeutics Inc.
Rank 231 of 363





PHARMACEUTICAL 2019

Oncternal Therapeutics Inc.
Rank 231 of 363

The relative strengths and weaknesses of Oncternal Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncternal Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 74% points. The greatest weakness of Oncternal Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is 36%, being 1.3% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	31,208
Cost of Goods Sold	0
Intangible Assets	94
Liabilities, Current	5,210
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	641
Other Revenues	0
Property and Equipment	19
Research and Development	29,669
Selling, General and Administrative Expense	9,390

Output Variable	Value in 1000 USD
Assets	31,321
Liabilities	5,210
Expenses	39,059
Revenues	0
Stockholders Equity	26,111
Net Income	-38,418
Comprehensive Net Income	-38,418
Economic Capital Ratio	36%